FTC Pay-For-Delay Stats Show Androgel Stakes Are High
Branded pharmaceutical companies and generic-drug makers have inked a record high number of potentially anti-competitive patent settlements over the past fiscal year, the Federal Trade Commission said Thursday, underscoring how much...To view the full article, register now.
Already a subscriber? Click here to view full article